Gaucher Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Gaucher Disease Treatment Market: Disease type (Type 1 (neuropathic forms), Type 2 (perinatal lethal form), Type 3 (Slow-neurologic decay form)), Medication (Enzyme replacement therapy (ERT), Substrate reduction therapy (SRT) and Surgical), By End User (Hospitals, Ambulatory Surgical Centers and Clinical research institutes), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Gaucher Disease Treatment Market size is valued at USD 1,522.3 million in 2021 and is expected to reach a value of USD 1,654.9 million by 2028, growing at a CAGR of 1.2% during the forecast period 2022 to 2028. The global market provides a detailed overview of the market and that can be segmented by disease type, medication and end user. By disease type, the gaucher disease treatment market has been segmented into type 1 (neuropathic forms), type 2 (perinatal lethal form) and Type 3 (Slow-neurologic decay form). The Type 1 (neuropathic forms) segment is likely to be the largest and fastest-growing segment in terms of technology. Based on medication, the gaucher disease treatment market is segmented into enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and surgical.  Among these, the substrate reduction therapy (SRT) segment is expected to have the fastest-growing market during the forecast period 2022-2028. On the basis of end-user, the market is segregated into hospitals, ambulatory surgical centers and clinical research institutes. The hospital’s segment held considerable market growth during the estimated period.

Gaucher Disease Treatment Market

MARKET SUMMARY
-
1.2% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 1.2%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Gaucher Disease Treatment Market

  • The gaucher disease treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The gaucher disease treatment market is segmented based on disease type, medication, end user and geography.
Key Players
  • Eli Lilly and Company
  • Enobia Pharma Inc.
  • Anthera Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical, Inc.
Gaucher Disease Treatment Market Drivers

The rising rates of gaucher disease in people around the world are raising the significant alarm, as the risk of contracting the disease rises with family consanguinity. The future of the industry is expected to be shaped by increased investments in rare illness research and development.


Asia-Pacific Got Significant Share

Gaucher Disease Treatment Market

Asia Pacific market is expected to witness the highest market share during the forecast period owing to increased consumer awareness of therapies, improved treatment availability, and a larger patient pool in the region. China and India are the major contributors to the growth of the market in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The gaucher disease treatment market report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The gaucher disease treatment market report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The gaucher disease treatment market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The gaucher disease treatment market report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The gaucher disease treatment market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Gaucher Disease Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The Gaucher Disease Treatment Marketis projected to expand at a CAGR of 1.2% during the forecast period.

The major players in the global gaucher disease treatment market are Abbott, Aptalis Pharma, Genzyme Corporation, GlaxoSmithKline, Pfizer, Inc., Shire Human Genetic Therapies, Inc., Eli Lilly and Company, Enobia Pharma Inc., Anthera Pharmaceuticals, Inc. and BioMarin Pharmaceutical, Inc.

Asia Pacific is the fastest-growing region for Gaucher Disease Treatment Market


Report

Table Of Content

1. Executive Summary
2. Global Gaucher Disease Treatment Market Introduction
2.1. Global Gaucher Disease Treatment Market – Taxonomy
2.2. Global Gaucher Disease Treatment Market –Definitions
2.2.1. By Disease Type
2.2.2. By Medication
2.2.3. By End User
2.2.4. By Region
3. Global Gaucher Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Gaucher Disease Treatment Market Dynamic Factors – Impact Analysis
3.6. Global Gaucher Disease Treatment Market – Competition Landscape
4. Global Gaucher Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Gaucher Disease Treatment Market, By Disease Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. Type 1 (neuropathic forms)
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Type 2 (perinatal lethal form)
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Type 3 (Slow-neurologic decay form)
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Gaucher Disease Treatment Market, By Medication, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1. Enzyme replacement therapy (ERT)
6.1.1. Imiglucerase (Cerezyme)
6.1.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. Velaglucerase alfa (VPRIV)
6.1.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.1.3. Taliglucerase alfa (Elelyso)
6.1.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3.3. Market Opportunity Analysis
6.1.4. Others
6.1.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.4.3. Market Opportunity Analysis
6.2. Substrate reduction therapy (SRT)
6.2.1. Glucosylceramide synthase inhibitors
6.2.1.1. Miglustat
6.2.1.1.1.        Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.1.1.2.        Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.1.1.3.        Market Opportunity Analysis
6.2.1.2. Eliglustat
6.2.1.2.1.        Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.1.2.2.        Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.1.2.3.        Market Opportunity Analysis
6.3. Surgical
6.3.1. Bone marrow transplant
6.3.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.1.3. Market Opportunity Analysis
6.3.2. Spleen Removal
6.3.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.2.3. Market Opportunity Analysis
7. Global Gaucher Disease Treatment Market, By End User, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. Hospitals
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Ambulatory Surgical Centers
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Clinical research institutes
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Gaucher Disease Treatment Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Gaucher Disease Treatment Market – Opportunity Analysis Index, By Disease Type, Medication, End User, and Region, 2022-2028
9. North America Gaucher Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Type 1 (neuropathic forms)
9.1.2. Type 2 (perinatal lethal form)
9.1.3. Type 3 (Slow-neurologic decay form)
9.2. Medication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Enzyme replacement therapy (ERT)
9.2.1.1. Imiglucerase (Cerezyme)
9.2.1.2. Velaglucerase alfa (VPRIV)
9.2.1.3. Taliglucerase alfa (Elelyso)
9.2.1.4. Others
9.2.2. Substrate reduction therapy (SRT)
9.2.2.1. Glucosylceramide synthase inhibitors
9.2.2.1.1.            Miglustat
9.2.2.1.2.            Eliglustat
9.2.3. Surgical
9.2.3.1. Bone marrow transplant
9.2.3.2. Spleen Removal
9.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Clinical research institutes
9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Gaucher Disease Treatment Market – Opportunity Analysis Index, By Disease Type, Medication, End User, and Country, 2022-2028
9.6. North America Gaucher Disease Treatment Market Dynamics – Trends
10. Europe Gaucher Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Type 1 (neuropathic forms)
10.1.2. Type 2 (perinatal lethal form)
10.1.3. Type 3 (Slow-neurologic decay form)
10.2. Medication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Enzyme replacement therapy (ERT)
10.2.1.1. Imiglucerase (Cerezyme)
10.2.1.2. Velaglucerase alfa (VPRIV)
10.2.1.3. Taliglucerase alfa (Elelyso)
10.2.1.4. Others
10.2.2. Substrate reduction therapy (SRT)
10.2.2.1. Glucosylceramide synthase inhibitors
10.2.2.1.1.          Miglustat
10.2.2.1.2.          Eliglustat
10.2.3. Surgical
10.2.3.1. Bone marrow transplant
10.2.3.2. Spleen Removal
10.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Clinical research institutes
10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Gaucher Disease Treatment Market – Opportunity Analysis Index, By Disease Type, Medication, End User, and Country, 2022-2028
10.6. Europe Gaucher Disease Treatment Market Dynamics – Trends
11. Asia-Pacific Gaucher Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Type 1 (neuropathic forms)
11.1.2. Type 2 (perinatal lethal form)
11.1.3. Type 3 (Slow-neurologic decay form)
11.2. Medication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Enzyme replacement therapy (ERT)
11.2.1.1. Imiglucerase (Cerezyme)
11.2.1.2. Velaglucerase alfa (VPRIV)
11.2.1.3. Taliglucerase alfa (Elelyso)
11.2.1.4. Others
11.2.2. Substrate reduction therapy (SRT)
11.2.2.1. Glucosylceramide synthase inhibitors
11.2.2.1.1.          Miglustat
11.2.2.1.2.          Eliglustat
11.2.3. Surgical
11.2.3.1. Bone marrow transplant
11.2.3.2. Spleen Removal
11.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Clinical research institutes
11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Gaucher Disease Treatment Market – Opportunity Analysis Index, By Disease Type, Medication, End User, and Country, 2022-2028
11.6. Asia-Pacific Gaucher Disease Treatment Market Dynamics – Trends
12. Latin America Gaucher Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Type 1 (neuropathic forms)
12.1.2. Type 2 (perinatal lethal form)
12.1.3. Type 3 (Slow-neurologic decay form)
12.2. Medication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Enzyme replacement therapy (ERT)
12.2.1.1. Imiglucerase (Cerezyme)
12.2.1.2. Velaglucerase alfa (VPRIV)
12.2.1.3. Taliglucerase alfa (Elelyso)
12.2.1.4. Others
12.2.2. Substrate reduction therapy (SRT)
12.2.2.1. Glucosylceramide synthase inhibitors
12.2.2.1.1.          Miglustat
12.2.2.1.2.          Eliglustat
12.2.3. Surgical
12.2.3.1. Bone marrow transplant
12.2.3.2. Spleen Removal
12.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals
12.3.2. Ambulatory Surgical Centers
12.3.3. Clinical research institutes
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Gaucher Disease Treatment Market – Opportunity Analysis Index, By Disease Type, Medication, End User, and Country, 2022-2028
12.6. Latin America Gaucher Disease Treatment Market Dynamics – Trends
13. Middle East and Africa Gaucher Disease Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
13.1. Disease Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Type 1 (neuropathic forms)
13.1.2. Type 2 (perinatal lethal form)
13.1.3. Type 3 (Slow-neurologic decay form)
13.2. Medication Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Enzyme replacement therapy (ERT)
13.2.1.1. Imiglucerase (Cerezyme)
13.2.1.2. Velaglucerase alfa (VPRIV)
13.2.1.3. Taliglucerase alfa (Elelyso)
13.2.1.4. Others
13.2.2. Substrate reduction therapy (SRT)
13.2.2.1. Glucosylceramide synthase inhibitors
13.2.2.1.1.          Miglustat
13.2.2.1.2.          Eliglustat
13.2.3. Surgical
13.2.3.1. Bone marrow transplant
13.2.3.2. Spleen Removal
13.3. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Clinical research institutes
13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. MEA Gaucher Disease Treatment Market – Opportunity Analysis Index, By Disease Type, Medication, End User, and Country, 2022-2028
13.6. MEA Gaucher Disease Treatment Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Abbott
14.2.2. Aptalis Pharma
14.2.3. Genzyme Corporation
14.2.4. GlaxoSmithKline
14.2.5. Pfizer, Inc.
14.2.6. Shire Human Genetic Therapies, Inc.
14.2.7. Eli Lilly and Company
14.2.8. Enobia Pharma Inc.
14.2.9. Anthera Pharmaceuticals, Inc.
14.2.10. BioMarin Pharmaceutical, Inc.
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • Abbott
  • Aptalis Pharma
  • Genzyme Corporation
  • GlaxoSmithKline
  • Pfizer, Inc.
  • Shire Human Genetic Therapies, Inc.
  • Eli Lilly and Company
  • Enobia Pharma Inc.
  • Anthera Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical, Inc.

Description

Gaucher Disease Treatment Market size is valued at USD 1,522.3 million in 2021 and is expected to reach a value of USD 1,654.9 million by 2028, growing at a CAGR of 1.2% during the forecast period 2022 to 2028. The global market provides a detailed overview of the market and that can be segmented by disease type, medication and end user. By disease type, the gaucher disease treatment market has been segmented into type 1 (neuropathic forms), type 2 (perinatal lethal form) and Type 3 (Slow-neurologic decay form). The Type 1 (neuropathic forms) segment is likely to be the largest and fastest-growing segment in terms of technology. Based on medication, the gaucher disease treatment market is segmented into enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and surgical.  Among these, the substrate reduction therapy (SRT) segment is expected to have the fastest-growing market during the forecast period 2022-2028. On the basis of end-user, the market is segregated into hospitals, ambulatory surgical centers and clinical research institutes. The hospital’s segment held considerable market growth during the estimated period.

Reviews

There are no reviews yet.

Be the first to review “Gaucher Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX